Fig. 1From: Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart reviewLung function in patients with and without allergic rhinitis (AR) before and after omalizumab administration. *p < 0.05. **p < 0.01. ***p > 0.05. FEV1, percentage of the forced expiratory volume in 1 s; FEV1%pre, forced expiratory volume in 1 s of predictedBack to article page